In a long-awaited decision published on 31 May 2021, the IAA found that Leadiant infringed Article 102 TFEU through a multifaceted strategy that led to it obtaining an excessive price for its CDCA Leadiant® medicine. A number...more
On October 4 the IAA has adopted the guidelines on how to structure an antitrust compliance programme and its treatment in the context of an antitrust investigation. They make clear that only compliance programme satisfying...more